Peptilogics Inc.
10:30 AM - 10:45 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation.
For more information about Peptilogics, visit Peptilogics or follow the company on Twitter and LinkedIn.
For more information about Peptilogics, visit Peptilogics or follow the company on Twitter and LinkedIn.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
PLG0206 is an investigational broad-spectrum, anti-bacterial and anti-biofilm peptide therapeutic currently in clinical development for the treatment of PJI. PLG0206 was designed with a unique mechanism of action that targets and disrupts bacterial membranes, allowing it to directly address the persistent bacterial pathogens within the biofilm that evade standard-of-care antibiotics. In both in vitro and in vivo non-clinical studies, PLG0206 has demonstrated best-in-class, rapidly bactericidal, broad-spectrum activity against a variety of pathogens including those identified by the World Health Organization and the Centers for Disease Control and Prevention as critical, urgent, or high-priority targets, regardless of resistance phenotype. PLG0206 has been granted Orphan Drug Designation for the treatment of PJI, has been designated as a Qualified Infectious Disease Product (QIDP), and has been granted Fast Track Designation by the US FDA.
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
